- Home
- AGEN vs VTVT Comparison
AGEN vs VTVT Comparison
Compare AGEN & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGEN | VTVT |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 143.7M |
| IPO Year | 1999 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AGEN | VTVT |
|---|---|---|
| Price | $3.16 | $33.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $14.50 | ★ $55.25 |
| AVG Volume (30 Days) | ★ 372.3K | 29.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $42,877,086.00 | $1,017,000.00 |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $68.25 | N/A |
| P/E Ratio | $8.04 | ★ N/A |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $1.38 | $14.00 |
| 52 Week High | $7.34 | $44.00 |
Technical Indicators
Market Signals| Indicator | AGEN | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 49.94 |
| Support Level | $2.90 | $33.62 |
| Resistance Level | $3.38 | $42.71 |
| Average True Range (ATR) | 0.18 | 3.30 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 52.69 | 31.70 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.